Enzalutamide Shows Superiority in Metastasis-Free Survival for Prostate Cancer Patients
A recent phase 3 trial has shed new light on the treatment of patients with prostate cancer who have high-risk biochemical recurrence. The study compared the efficacy and safety of enzalutamide plus androgen-deprivation therapy and enzalutamide monotherapy with androgen-deprivation therapy alone.
HCN Medical Memo
The findings from this study could have significant implications for healthcare professionals treating patients with prostate cancer. The superior metastasis-free survival rates observed with enzalutamide plus leuprolide and enzalutamide monotherapy could lead to a paradigm shift in the treatment of patients with high-risk biochemical recurrence. This could potentially impact patient care by providing more effective treatment options.
- The study enrolled patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less.
- A total of 1,068 patients underwent randomization.
- Patients were randomly assigned to receive enzalutamide (160 mg) daily plus leuprolide every 12 weeks (combination group), placebo plus leuprolide (leuprolide-alone group), or enzalutamide monotherapy (monotherapy group).
- The primary end point was metastasis-free survival, as assessed by blinded independent central review.
According to the American Cancer Society, prostate cancer is the second most common cancer among men in the United States.
- At 5 years, metastasis-free survival was 87.3% in the combination group, 71.4% in the leuprolide-alone group, and 80.0% in the monotherapy group.
- Enzalutamide plus leuprolide was superior to leuprolide alone; enzalutamide monotherapy was also superior to leuprolide alone.
- No new safety signals were observed, with no substantial between-group differences in quality-of-life measures.
More on Prostate Cancer